



ASX Announcement
23 October 2023

OPTISCAN ANNOUNCES CHIEF OPERATING OFFICER APPOINTMENT

- Brendan Fafiani joins Optiscan as Chief Operating Officer
- Brings significant leadership experience and success in product development and commercialisation of medical devices globally
- Appointment enhances internal capabilities as the Company looks to accelerate its commercial rollout and US expansion

Optiscan Imaging Limited (ASX: OIL) is pleased to announce a key leadership appointment reflecting the continued commercial expansion of the Company.

The Company is delighted to announce the appointment of **Brendan Fafiani** to the role of **Chief Operating Officer**. Effective 6 November 2023, Brendan will assume responsibility for Optiscan's operations at its Melbourne headquarters, leading the development of the Company's operational planning and overseeing its commercialisation strategy encompassing sales and marketing, as well as managing personnel, and customer and development efforts. Optiscan CEO, Dr Camile Farah, will continue to focus on key investor relations, stakeholder engagement initiatives, and the US expansion plan.

Brendan joins Optiscan from Cyban Pty Ltd, where, as the Chief Executive Officer he led the initial commercialisation of a pioneering non-invasive Brain Oxygen and Intracranial Pressure monitor. Prior to this, as Vice President of Product and General Manager at Global Kinetics, Brendan led the product development of a novel Parkinson's disease monitor through regulatory clearance and launch into the US, Europe, and APAC. Prior to relocating to Australia, as Associate Director Operations within Merck KGaA's Medical Device Global Business Franchise, headquartered in Switzerland, he was responsible for the lifecycle management of a large portfolio of device and digital technologies.

Brendan brings a wealth of expertise in the introduction of new technologies into existing treatment pathways, both in start-ups undergoing rapid growth and large multinational corporations, across neurodegenerative and cardiometabolic diseases, endocrinology and acquired brain injury fields.

Optiscan CEO and Managing Director Dr Camile Farah, stated, "The appointment of Brendan follows a thorough and comprehensive executive search as we move beyond our inflection point in FY23, and pivot into accelerating revenue generation in FY24 and beyond. I am delighted to welcome Brendan into Optiscan to lead key elements of our business, shape and implement key commercial excellence processes and scale our operation."

The decision to appoint a Chief Operating Officer is a key enablement strategy for Optiscan. It enhances the functionality of the Company's global headquarters in Melbourne, facilitates integration with its US commercial

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com

hub, and advances pursuit of key strategic priorities that will benefit the Company and shareholder base greatly in the future.

Dr Camile Farah, continued, “Brendan brings the ideal blend of skills and expertise crucial for our current growth phase, aligning perfectly with planned product innovation, development of new clinical devices, and evolution into a digital solutions company offering revolutionary image guided surgical solutions coupled with proprietary world-class Artificial Intelligence (AI) and Telepathology diagnostic support functionality. I look forward to working closely with Brendan at our Melbourne headquarters, while continuing to focus on our US expansion plans. I will provide further updates on additional appointments and initiatives in due course.”

This announcement has been authorised for release by the Board of Optiscan.

– ends –

For investor queries, please contact:

Dr. Camile Farah
Chief Executive Officer & Managing Director
Optiscan Imaging Ltd
E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333
A: 16 Miles St, Mulgrave VIC 3170, Australia
W: www.optiscan.com